February 9, 2006 -- Martek Biosciences rose sharply after raising its guidance for Q1 revenue; Isis Pharma reported that its cardiovascular drug dropped triglycerides levels by a median 46%; Elan sold the European rights for Prialt, a non-opioid pain killer, for $50 million upfront and up to $50 more in milestones; the FDA says 51 patients in the US have died while taking drugs for ADHD; Bristol-Myers Squibb won preliminary court approval of a $185 million settlement with investors; Biogen Idec has been warned by the FDA about misleading claims in advertising for its cancer drug; and GlaxoSmithKline is interested in the non-prescription division of Pfizer, which could be sold for $10 billion. The Centient Biotech 200™ was off 15 points at 3859.34, a .40% drop. More details...
